STOCK TITAN

CHE insider sale notice: 556 common shares planned for 07/31/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.

Positive

  • Transparent disclosure of the intended sale including broker, exchange, and aggregate market value
  • Acquisition details provided showing the shares were received as stock awards with dates and amounts

Negative

  • None.

Insights

TL;DR: Routine insider sale notice showing a small planned disposition of vested stock awards, with no recent sales reported.

The Form 144 discloses a proposed sale of 556 common shares valued at $232,410.94, executed through Merrill Lynch and scheduled for 07/31/2025. The holdings derive from two stock awards vested in 2022 and 2023. There are no reported sales in the prior three months, indicating this filing documents a planned, rather than recurring, disposition. For investors, this appears procedural and consistent with normal post-vesting sales by insiders, with no additional operational or financial data disclosed.

TL;DR: Compliance-focused filing that meets disclosure requirements under Rule 144; contains standard attestations.

The notice includes the required acquisition details, broker information, and a signer representation regarding material undisclosed information, satisfying Rule 144 procedural disclosures. The acquisition types are listed as stock awards with payment dates matching grant/vesting dates. The absence of prior three-month sales simplifies aggregation considerations. From a governance perspective, the filing reflects routine insider transparency without revealing governance or control changes.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Chemed Corporation's Form 144 filed for CHE disclose?

The filing discloses a proposed sale of 556 common shares valued at $232,410.94, to be executed on or about 07/31/2025 through Merrill Lynch on the NYSE.

How were the shares being sold by CHE acquired?

The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates.

Did the filer report any Chemed (CHE) sales in the past three months?

No. The Form 144 lists Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

What broker and exchange are named in the CHE Form 144?

The broker listed is Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL, and the exchange named is the NYSE.

Does the filing include any statement about undisclosed material information?

Yes. The signer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.